News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
479,939 Results
Type
Article (26412)
Company Profile (183)
Press Release (453344)
Section
Business (135207)
Career Advice (458)
Deals (22935)
Drug Delivery (36)
Drug Development (79688)
Employer Resources (45)
FDA (13107)
Job Trends (9735)
News (249623)
Policy (20573)
Tag
Academia (1859)
Alliances (37950)
Alzheimer's disease (1213)
Approvals (13020)
Artificial intelligence (116)
Bankruptcy (150)
Best Places to Work (8336)
Biotechnology (142)
Breast cancer (111)
Cancer (986)
Cardiovascular disease (74)
Career advice (403)
CAR-T (66)
Cell therapy (205)
Clinical research (64305)
Collaboration (313)
Compensation (143)
COVID-19 (2062)
C-suite (79)
Cystic fibrosis (70)
Data (989)
Diabetes (119)
Diagnostics (5207)
Earnings (49524)
Events (74376)
Executive appointments (234)
FDA (13545)
Funding (280)
Gene therapy (136)
GLP-1 (441)
Government (2436)
Healthcare (14032)
Infectious disease (2123)
Inflammatory bowel disease (107)
IPO (11388)
Job creations (1705)
Job search strategy (371)
Layoffs (255)
Legal (3061)
Lung cancer (158)
Manufacturing (113)
Medical device (9540)
Medtech (9542)
Mergers & acquisitions (11681)
Metabolic disorders (296)
Neuroscience (1460)
NextGen Class of 2024 (4022)
Non-profit (2506)
Northern California (1264)
Obesity (151)
Opinion (125)
Parkinson's disease (71)
Patents (63)
People (39395)
Phase I (20588)
Phase II (28635)
Phase III (20821)
Pipeline (348)
Postmarket research (2112)
Preclinical (7531)
Radiopharmaceuticals (237)
Rare diseases (182)
Real estate (3372)
Regulatory (16120)
Research institute (1947)
Southern California (1109)
Startups (2634)
United States (10541)
Vaccines (382)
Weight loss (93)
Date
Today (197)
Last 7 days (872)
Last 30 days (3093)
Last 365 days (30411)
2024 (27197)
2023 (34418)
2022 (43476)
2021 (45640)
2020 (42138)
2019 (32467)
2018 (24413)
2017 (25401)
2016 (23366)
2015 (27360)
2014 (20085)
2013 (15620)
2012 (16389)
2011 (16946)
2010 (15954)
Location
Africa (414)
Arizona (98)
Asia (35504)
Australia (5978)
California (2769)
Canada (966)
China (221)
Colorado (114)
Connecticut (118)
Europe (67444)
Florida (332)
Georgia (88)
Illinois (197)
Indiana (141)
Kansas (73)
Maryland (403)
Massachusetts (2112)
Michigan (96)
Minnesota (165)
New Jersey (740)
New York (758)
North Carolina (609)
Northern California (1264)
Ohio (96)
Pennsylvania (664)
South America (551)
Southern California (1109)
Texas (376)
Utah (70)
Washington State (292)
479,939 Results for "clinical genomics pty ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Halia Therapeutics Joins Forces with Southern Star Research Pty Ltd to Advance Clinical Development of Novel LRRK2 Inhibitor, HT-4253 for Neurodegenerative Diseases
September 3, 2024
·
4 min read
BioCapital
Eilean Therapeutics Joins The Leukemia & Lymphoma Society’s Groundbreaking Beat AML® Master Clinical Trial
Eilean Therapeutics AU Pty Ltd has joined The Leukemia & Lymphoma Society in the groundbreaking collaborative Beat AML® Master Clinical Trial.
June 11, 2024
·
4 min read
CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer
May 23, 2024
·
2 min read
Business
Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina’s Growth Vision
Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced the appointment of Mark W. Womack as a Director of the Board.
March 5, 2024
·
3 min read
CARTHERICS SECURES AUSTRALIAN PATENT FOR INNOVATIVE CANCER CELL THERAPY
Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce...
June 12, 2024
·
2 min read
Press Releases
QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting
November 6, 2024
·
3 min read
BioForest
Independent Studies Presented at ESCMID Global Demonstrate the Clinical Utility of SeptiCyte® RAPID in Patients Suspected of Sepsis, Including in Polytrauma Patients
Immunexpress, Pty Ltd. today announced the presentation of two posters evaluating SeptiCyte® RAPID at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 2024, to take place from April 27 – 30 in Barcelona, Spain.
April 17, 2024
·
5 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
BioMidwest
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.
June 21, 2024
·
3 min read
Business
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.
April 8, 2024
·
8 min read
1 of 47,994
Next
